

# 19th Annual Pharmaceutical and Medical Device Compliance Congress

MANDARIN ORIENTAL • WASHINGTON, DC  
NOVEMBER 7 - 9, 2018

SPONSORED BY



Follow Pharma Congress on:



## Global Compliance Function Harmonization

November 7, 2018, 11 a.m.




# Panel Introductions

## Moderators:



**Laura Skinner, MBA**  
Senior Manager, Regulatory & Compliance  
Life Sciences Leader, Deloitte & Touche LLP  
Austin, TX




**Clarissa Crain**  
Senior Manager, Regulatory & Compliance  
Life Sciences Leader, Deloitte & Touche LLP  
Philadelphia, PA

---

## Panelists:



**Scott Bass, JD**  
Partner and Head, Global Life Sciences  
Sidley Austin LLP  
New York, NY




**Robert Ladd, JD**  
Vice President, Global Head, Integrity and  
Compliance, Oncology  
Novartis  
East Hanover, NJ




**Melissa Murphy, MBA**  
Senior Compliance Specialist  
Office of Ethics and Compliance  
Medtronic  
Minneapolis, MN


## ► Today's Discussion



Trends in global markets driving critical compliance considerations



Governance structures including global view to risk prioritization, standards, and control requirements



Operating and resource model to meet global complexities

## Text Option Polling Instructions:

1. Text Account Name **PC17** to **22333**
2. When a poll is shown, text your response.
3. Type "Leave" to exit the account.

# Audience Polling #1

► What global markets does your organization engage in? *(select all that apply)*

- A. North America
- B. Asia / Pacific
- C. India
- D. EU / EMEA
- E. Latin America
- F. Africa
- G. Middle East
- H. Other





## What global market does your organization engage in?

North America

Asia/Pacific

India

EU/EMEA

Latin America

Africa

Middle East

Other

## Audience Polling #2

► How is your compliance function organized globally?  
*(select the one that applies best)*

- A. Centralized
- B. Decentralized
- C. Hybrid
- D. Other
- E. Not Applicable



## How is your compliance function organized globally? (select the one that applies best)

Centralized

Decentralized

Hybrid

Other

Not  
applicable



# Audience Polling #3

► Is your organization currently going through or planning a realignment of your global compliance structure?

A. Yes

B. No

C. Uncertain



# Is your organization currently going through or planning a realignment of your global compliance structure?

Yes

No

Uncertain

# Today's Panel

## Moderators:



**Laura Skinner, MBA**  
Senior Manager, Regulatory & Compliance  
Life Sciences Leader, Deloitte & Touche LLP  
Austin, TX



**Clarissa Crain**  
Senior Manager, Regulatory & Compliance  
Life Sciences Leader, Deloitte & Touche LLP  
Philadelphia, PA

---

## Panelists:



▶ **Scott Bass, JD**  
▶ Partner and Head, Global Life Sciences  
▶ Sidley Austin LLP  
▶ New York, NY



**Robert Ladd, JD**  
Vice President, Global Head, Integrity and  
Compliance, Oncology  
Novartis  
East Hanover, NJ



**Melissa Murphy, MBA**  
Senior Compliance Specialist  
Office of Ethics and Compliance  
Medtronic  
Minneapolis, MN

## Sample Discussion Topics

- What trends are you seeing the market place regarding operating model designs (e.g. CoE, Regionalization, etc)?
- What markets are presenting the greatest challenge and how are organizations addressing these challenges?
- When resources for compliance are shared (part-time) functions associated with Compliance, how does this effect the compliance organization and priorities (e.g. Legal, Quality, Country Manager, etc)?
- What are the most challenging operational elements you see global compliance teams dealing with? (e.g. resourcing, transparency, global risk assessment)
- What are the most challenging governance challenges for global compliance? (e.g. HCP engagement governance, global corporate view of compliance risk, written standards)

Questions?

Thank you!

